

# Benjamin H Durham

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1480694/publications.pdf>

Version: 2024-02-01

61  
papers

4,873  
citations

109137

35  
h-index

133063

59  
g-index

62  
all docs

62  
docs citations

62  
times ranked

7041  
citing authors

#	ARTICLE	IF	CITATIONS
1	ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. <i>Blood</i> , 2022, 139, 256-280.	0.6	60
2	<i>RACGAP1</i> variants in a sporadic case of CDA III implicate the dysfunction of centralspindlin as the basis of the disease. <i>Blood</i> , 2022, 139, 1413-1418.	0.6	9
3	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2022, 386, 735-743.	13.9	87
4	First report of bilateral breast-implant associated anaplastic large cell lymphoma caused by identical T-cell clone. <i>Leukemia and Lymphoma</i> , 2022, 63, 2747-2750.	0.6	2
5	Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. <i>Nature Genetics</i> , 2021, 53, 707-718.	9.4	61
6	Histiocytosis and the nervous system: from diagnosis to targeted therapies. <i>Neuro-Oncology</i> , 2021, 23, 1433-1446.	0.6	33
7	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	13.5	131
8	Mutant SF3B1 promotes AKT- and NF- $\kappa$ B-driven mammary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	22
9	MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a034892.	2.9	17
10	MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. <i>Leukemia</i> , 2021, .	3.3	3
11	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . <i>Haematologica</i> , 2020, 105, e5-e8.	1.7	34
12	PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN. <i>Cancer Discovery</i> , 2020, 10, 1742-1757.	7.7	55
13	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. <i>Cancers</i> , 2020, 12, 3240.	1.7	5
14	Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. <i>Neuro-Oncology</i> , 2020, 22, 979-992.	0.6	31
15	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. <i>Blood</i> , 2020, 135, 1929-1945.	0.6	191
16	<i>ZRSR2</i> Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of <i>LZTR1</i> . <i>Blood</i> , 2020, 136, 10-11.	0.6	1
17	Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation. <i>Cell Stem Cell</i> , 2019, 25, 682-696.e8.	5.2	106
18	A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1. <i>Cancer Discovery</i> , 2019, 9, 962-979.	7.7	58

#	ARTICLE	IF	CITATIONS
19	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1149-1157.	1.9	26
20	Efficacy of MEK inhibition in patients with histiocytic neoplasms. <i>Nature</i> , 2019, 567, 521-524.	13.7	222
21	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019, 25, 1839-1842.	15.2	122
22	An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. <i>Oncogene</i> , 2019, 38, 671-686.	2.6	39
23	Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages. <i>Seminars in Cell and Developmental Biology</i> , 2019, 86, 62-76.	2.3	54
24	PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN. <i>Blood</i> , 2019, 134, 473-473.	0.6	4
25	Stag2 Regulates Hematopoietic Differentiation and Self-Renewal through Alterations in Gene Expression and Topological Control. <i>Blood</i> , 2019, 134, 279-279.	0.6	0
26	Single-agent dabrafenib for <i>BRAF</i> V600E-mutated histiocytosis. <i>Haematologica</i> , 2018, 103, e177-e180.	1.7	40
27	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. <i>Blood</i> , 2018, 131, 2877-2890.	0.6	335
28	Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. <i>Cell Host and Microbe</i> , 2018, 23, 447-457.e4.	5.1	86
29	Novel activating <i>BRAF</i> fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26699.	0.8	16
30	Vemurafenib for <i>BRAF</i> V600E-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. <i>JAMA Oncology</i> , 2018, 4, 384.	3.4	280
31	The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. <i>Modern Pathology</i> , 2018, 31, 581-597.	2.9	102
32	Erdheim-Chester Disease. , 2018, , 313-338.		2
33	Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene <i>U2af1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10437-E10446.	3.3	59
34	Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. <i>Blood</i> , 2018, 132, 1265-1278.	0.6	39
35	Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. <i>Cancer Cell</i> , 2018, 34, 225-241.e8.	7.7	162
36	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3819-3825.	3.9	45

#	ARTICLE	IF	CITATIONS
37	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. <i>Blood</i> , 2018, 132, 49-49.	0.6	10
38	The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease. <i>Blood</i> , 2018, 132, 2397-2397.	0.6	1
39	Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. <i>Blood</i> , 2017, 129, 1779-1790.	0.6	18
40	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nature Communications</i> , 2017, 8, 15429.	5.8	55
41	Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. <i>Blood</i> , 2017, 130, 167-175.	0.6	136
42	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. <i>Blood</i> , 2017, 130, 397-407.	0.6	112
43	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. <i>Blood</i> , 2017, 130, 176-180.	0.6	98
44	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. <i>Nature</i> , 2017, 549, 389-393.	13.7	144
45	miR-99 regulates normal and malignant hematopoietic stem cell self-renewal. <i>Journal of Experimental Medicine</i> , 2017, 214, 2453-2470.	4.2	44
46	Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. <i>Blood</i> , 2017, 130, 1644-1648.	0.6	82
47	High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. <i>Blood</i> , 2017, 130, 1007-1013.	0.6	98
48	The clinical spectrum of Erdheim-Chester disease: an observational cohort study. <i>Blood Advances</i> , 2017, 1, 357-366.	2.5	163
49	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. <i>Blood</i> , 2017, 130, 794-794.	0.6	0
50	Histiocytic neoplasms in the era of personalized genomic medicine. <i>Current Opinion in Hematology</i> , 2016, 23, 416-425.	1.2	37
51	MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. <i>Nature Communications</i> , 2016, 7, 10739.	5.8	27
52	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. <i>Nature Medicine</i> , 2016, 22, 672-678.	15.2	301
53	Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. <i>Blood</i> , 2016, 128, 1896-1898.	0.6	24
54	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	15.2	195

#	ARTICLE	IF	CITATIONS
55	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine, 2016, 22, 578-579.	15.2	7
56	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	7.7	372
57	Sonographic appearance of a dermoid cyst (mature cystic teratoma) of the spleen. Journal of Clinical Ultrasound, 2015, 43, 132-134.	0.4	2
58	Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine, 2015, 21, 1344-1349.	15.2	297
59	Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. European Journal of Cancer, 2015, 51, 2413-2422.	1.3	79
60	Rapidly Progressive Primary Leptomeningeal Atypical Teratoid/Rhabdoid Tumor. Journal of Child Neurology, 2012, 27, 1597-1601.	0.7	6
61	Resistant Fusarium Keratitis Progressing to Endophthalmitis. Eye and Contact Lens, 2012, 38, 331-335.	0.8	19